FEBRUARY 2022
Greetings!

We are gearing up for conferences that are finally happening live! These events are a great opportunity to get a close look at or demo the SYNTAX System. See you there!
UPCOMING EVENTS
COVID-19 Webinar (in partnership with Select Science)
March 3, 2022 17:00 CET | 11:00 EST | 08:00 PST

  • Webinar Title: How to rapidly produce expression vectors for SARS-CoV-2 spike variants using Enzymatic DNA Synthesis (EDS) oligos, presented by Steven Quistad, Ph.D. and Bailey Schmidt
March 27-30, 2022 | Palm Springs, CA USA | Booth #220

  • Networking Event | Mar 28 9:00pm | The Village Pub Pick up drink tickets at the booth! (ABRF badge required)

  • Technology Showcase | Mar 29 7:30 - 8:30am | Smoketree AB

  • EyeOpener Talk | Mar 30 9:30am: Using Enzymatic DNA Synthesis to Build Custom Library Adaptors for Controlling Real-Time Nanopore Sequencing, presented by Tim Mercer, Ph.D. from the University of Queensland
March 29-30, 2022 | Boston, MA USA | Booth #19

  • Technology Showcase | Mar 29 12:30 - 1:00pm Breakout Room 3
April 12-14, 2022 | Oakland, CA USA | Booth #34

  • Spotlight Talk | Apr 13 10:40am | Main Stage: SYNTAX System — Same-Day DNA Synthesis to Power Molecular Biology & Genomics Workflows, presented by Thomas Ybert, Ph.D., DNA Script CEO & Founder
June 6-9, 2022 | Orlando, FL USA | Jade-Lexington Suite
>> WANT MORE? Check Out Our Events
FEATURE ARTICLE
In this article, Thomas Ybert, Ph.D. reflects on the history of DNA synthesis and the direction the industry is taking. Enzymatic DNA Synthesis (EDS) is gaining momentum as a safer, more sustainable method that puts workflow control and on-demand DNA back in the hands of researchers.

As a pioneer in developing EDS, and the first to launch the world's first enzymatic DNA printer, the SYNTAX System, Ybert discusses EDS as the future of synthetic biology and accelerating innovations.  
IN THE NEWS
DNA Script will develop a fully-automated and deployable system to synthesize DNA templates for RNA production with a short turnaround time under Wellcome Leap’s RNA Response + Readiness (R3) program.
The Science Advisory Board featured DNA Script in their article about the top investments in biotools. Thomas Ybert, Ph.D. shares DNA Script's plans for 2022 to advance the Enzymatic DNA Synthesis-powered SYNTAX System and the synthetic biology industry as a whole.
We're proud to be a member of the Biotech Social Pact. This European initiative works alongside policymakers, investors, and health authorities to ensure patient welfare and unmet needs are at the forefront of research and healthcare, with equal access to innovative medicines.  
For Research Use Only. Not for use in diagnostic procedures.
You are receiving this email because of your work in molecular biology and genomics applications.
If you no longer want to receive emails from DNA Script, click Unsubscribe below.